By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Xanthus Pharmaceuticals, Inc. 

300 Technology Square

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-225-0522 Fax: 617-225-0525


Company News
Antisoma PLC (ASM.L) To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M 5/16/2008 8:45:16 AM
Xanthus Pharmaceuticals, Inc.'s Symadex Demonstrates Ability to Increase Spinal Cord Remyelination in Multiple Sclerosis Model 12/11/2007 11:51:54 AM
Xanthus Pharmaceuticals, Inc.' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia 12/10/2007 9:00:03 AM
European Commission Grants Orphan Drug Designation to Xanthus Pharmaceuticals, Inc.'s Xanafide for the Treatment of Acute Myeloid Leukemia 10/26/2007 10:28:49 AM
Xanthus Pharmaceuticals, Inc. Presents Data from FLT3 Autoimmune Program Supporting Novel Cell-Targeted Mechanism for Disease Attenuation 10/15/2007 11:12:24 AM
Xanthus Pharmaceuticals, Inc. to Present at the Biotechnology Industry Organization (BIO) Investor Forum 2007 Conference 10/3/2007 9:59:57 AM
Xanthus Life Sciences Presents In Vitro Data Demonstrating That Symadex Is A Potent And Selective Inhibitor Of FLT3 9/15/2006 11:08:46 AM
Xanthus Life Sciences Changes Name To Xanthus Pharmaceuticals, Inc. 2/22/2006 10:25:58 AM
Xanthus Life Sciences' Symadex(TM) Shows Remyelination In Multiple Sclerosis Animal Model 2/13/2006 11:32:12 AM
Xanthus Life Sciences To Provide Update At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2006 2/9/2006 12:59:04 PM